Literature DB >> 8491236

Bioavailability of controlled release carbamazepine estimated by mixed effect modelling.

R Miller1, T M Ludden.   

Abstract

The absorption properties of a conventional tablet of carbamazepine (T) and a controlled release form of carbamazepine (TCR) have been compared using a nonlinear mixed effect model (NONMEM). Plasma carbamazepine concentration data were obtained from an open, steady-state, crossover bioavailability study in which 494 measurements were obtained from 13 patients, with an equal number of samples per patient for each dosage form. The pharmacokinetic model used as a one-compartment open model with first-order absorption and elimination. The objective function was used as a measure of the goodness of fit of the model to the data. Body weight was an important determinant of carbamazepine clearance (CL) but not volume of distribution (V). Accounting for the interindividual variability in volume of distribution did not significantly influence the objective function. Including different rates of absorption (ka) for the two dosage forms resulted in a significant improvement in the objective function, as well as reducing the interindividual variability in the rate of absorption. Adding a parameter for relative bioavailability (f) of TCR improved the objective function statistically, but an unrealistic value for V was obtained, and the absorption and elimination rates appeared to be transposed in the classical "flip-flop" manner. Fixing V to the value obtained before introducing f did not change the objective function and permitted estimation of f without the confounding influence of excessive parameters.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8491236     DOI: 10.1007/BF00271363

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  Application of the NONMEM method to evaluation of the bioavailability of drug products.

Authors:  N Kaniwa; N Aoyagi; H Ogata; M Ishii
Journal:  J Pharm Sci       Date:  1990-12       Impact factor: 3.534

2.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  Application of NONMEM to routine bioavailability data.

Authors:  D A Graves; I Chang
Journal:  J Pharmacokinet Biopharm       Date:  1990-04

4.  A note on confidence intervals with extended least squares parameter estimates.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1987-02

5.  Statistical aspects of comparative bioavailability trials.

Authors:  W J Westlake
Journal:  Biometrics       Date:  1979-03       Impact factor: 2.571

6.  Carbamazepine metabolism in man. Induction and pharmacogenetic aspects.

Authors:  M Eichelbaum; T Tomson; G Tybring; L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

  6 in total
  6 in total

Review 1.  Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug development.

Authors:  Jaime A Yáñez; Connie M Remsberg; Casey L Sayre; M Laird Forrest; Neal M Davies
Journal:  Ther Deliv       Date:  2011-05

2.  Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam.

Authors:  M Hossain; E Wright; R Baweja; T Ludden; R Miller
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

3.  A novel extravascular input function for the assessment of drug absorption in bioavailability studies.

Authors:  M Weiss
Journal:  Pharm Res       Date:  1996-10       Impact factor: 4.200

4.  Pharmacokinetics of carbamazepine derived from a new tablet formulation.

Authors:  J Popović; M Mikov; V Jakovljevic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Oct-Dec       Impact factor: 2.441

5.  Evaluation of different metrics as indirect measures of rate of drug absorption from extended release dosage forms at steady-state.

Authors:  C Reppas; L F Lacey; O N Keene; P Macheras; A Bye
Journal:  Pharm Res       Date:  1995-01       Impact factor: 4.200

6.  Reduced Systemic and Brain Exposure with Inhibited Liver Metabolism of Carbamazepine After Its Long-Term Combination Treatment with Piperine for Epilepsy Control in Rats.

Authors:  Tianjing Ren; Min Xiao; Mengbi Yang; Jiajia Zhao; Yufeng Zhang; Mengyun Hu; Yan Cheng; Hong Xu; Chunbo Zhang; Xiaoyu Yan; Zhong Zuo
Journal:  AAPS J       Date:  2019-07-18       Impact factor: 4.009

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.